GSK plc (LON:GSK) Receives Average Recommendation of "Hold" from Analysts

Key Points

• GSK has an average “Hold” rating from seven analysts: four holds, two buys, and one sell. The average 12-month price target is GBX 2,048.57, compared with a share price of about GBX 1,917.
• Recent analyst actions were mixed: Jefferies reaffirmed a “Buy” rating with a GBX 2,500 target, Deutsche Bank maintained “Hold” at GBX 2,000, and Citigroup cut its target to GBX 2,100 with a “Neutral” rating.
• GSK reported quarterly earnings of GBX 10.80 per share, with a 14.52% net margin and 28.35% return on equity. Shares were down 0.5% at the time of the report, while insiders had purchased shares during the prior 90 days.

GSK plc (LON:GSK - Get Free Report) has been assigned an average rating of "Hold" from the seven brokerages that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is GBX 2,048.57.

GSK has been the topic of a number of research analyst reports. Jefferies Financial Group reiterated a "buy" rating and issued a GBX 2,500 target price on shares of GSK in a research note on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft restated a "hold" rating and set a GBX 2,000 price target on shares of GSK in a research note on Tuesday, August 4th. Finally, Citigroup lowered their price target on shares of GSK from GBX 2,250 to GBX 2,100 and set a "neutral" rating on the stock in a report on Wednesday, May 6th.

GSK Stock Down 0.5%

Shares of LON:GSK opened at GBX 1,917.43 on Tuesday. GSK has a 1 year low of GBX 1,288.61 and a 1 year high of GBX 2,282. The company has a market capitalization of £76.80 billion, a PE ratio of 16.28, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29. The business has a fifty day moving average price of GBX 1,941.69 and a two-hundred day moving average price of GBX 1,996.20. The company has a debt-to-equity ratio of 103.36, a current ratio of 0.82 and a quick ratio of 0.73.

GSK (LON:GSK - Get Free Report) last issued its quarterly earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. Analysts forecast that GSK will post 175.980975 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Jeannie Lee bought 802 shares of the stock in a transaction on Monday, June 22nd. The shares were purchased at an average cost of GBX 5,069 per share, for a total transaction of £40,653.38. Also, insider Jonathan Symonds bought 1,550 shares of the stock in a transaction on Friday, June 19th. The stock was purchased at an average price of GBX 1,935 per share, for a total transaction of £29,992.50. Insiders bought 3,618 shares of company stock valued at $13,481,942 over the last ninety days. 0.20% of the stock is currently owned by insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source